Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourLeaning Bearish
15 minAscending Triangle
5 minBullish
Daily trend turns up above $42.06
Key levels
Resistance$56.33
Resistance$51.59
Support$48.52
Support$45.87
Latest news & SEC filings
AnalystAnalyst Keeps $78 Target and Buy Rating on Enliven Therapeutics
All ELVN news →Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule medicines. Its lead candidate, ELVN-001, is an oral drug that blocks a specific cancer-driving protein and is being tested in a Phase 1 trial in patients with chronic myeloid leukemia. The company also has earlier-stage research programs in other diseases, including Graves' disease. It operates in the United States and holds worldwide rights to its pipeline.
Based on the company's 10-K filed Mar 3, 2026.
Nasdaq · Healthcare
SEPT Low Target
$70.00
SEPT Mid Target
$75.00
SEPT High Target
$82.00
Analyst Consensus
$75.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ELVN.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$65.09
12
Moat Score
NONE
4/9
Piotroski Score
96.3
Altman Z-Score
Insider Signal
SELLING
0 buys / 10 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Kunkel Lori Anne | director | Buy | 3,741 | $4K | Oct 30, 2026 |
| Kunkel Lori Anne | director | Buy | 7,300 | $134K | Oct 30, 2026 |
| Hohl Benjamin | officer | Buy | 6,018 | $89K | Oct 19, 2026 |
| Hohl Benjamin | officer | Sale | 6,018 | $232K | Oct 19, 2026 |
| Collins Helen Louise | officer | Buy | 5,000 | $12K | Oct 19, 2026 |
| Collins Helen Louise | officer | Sale | 5,000 | $192K | Oct 19, 2026 |
| Garland J. Scott | director | Buy | 13,000 | $201K | Oct 1, 2026 |
| Garland J. Scott | director | Sale | 13,000 | $607K | Oct 1, 2026 |
| Hohl Benjamin | officer | Buy | 3,982 | $59K | Sep 17, 2026 |
| Hohl Benjamin | officer | Sale | 3,535 | $177K | Sep 17, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
3.17%
FCF Growth YoY
3.8%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for ELVN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:08 | $51.19 | 4,440 | $$227K | BUY |
| 21:00:08 | $51.19 | 3,047 | $$156K | BUY |
| 21:00:01 | $51.19 | 1,100 | $$56K | BUY |
| 20:59:41 | $51.18 | 1,053 | $$54K | BUY |
| 20:59:28 | $51.28 | 4,203 | $$216K | MIDPOINT |
5 dark pool trades shown · $$709K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for ELVN. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup — $ELVN (Enliven Therapeutics, Inc.) Price: $59.63 | Zone: $52.73 — $62.32 Conviction: HIGH | Analyst upside: +35.2% Near resistance (72% of range) — breakout watch. Strong positive news ...
Zone Setup -- $ELVN (Enliven Therapeutics, Inc.) Price: $51.73 | Zone: $49.83 to $52.38 Conviction: HIGH | Analyst upside: +28.4% Near resistance (74% of range) — breakout watch. Strong positive new...
Join 3,500+ traders discussing ELVN in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
SEPT's Trading AI has generated a free, downloadable PDF research report for Enliven Therapeutics, Inc. (ELVN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Enliven Therapeutics, Inc. (ELVN) is at $51.19, down 0.02% (-$0.01) at the Nov 11, 2026 close.
Latest ELVN news — Nov 6, 2026: Analyst Keeps $78 Target and Buy Rating on Enliven Therapeutics
The average analyst price target for ELVN is $75.00, ranging from $70 to $82, based on 9 analysts. Latest: HC Wainwright & Co. maintains on Oct 19, 2026.
Analyst ratings for ELVN: 0 Buy, 17 Hold, 0 Sell — consensus Hold.
ELVN last reported on Nov 5, 2026: EPS -$0.36 vs -$0.45 expected — a beat of 19.6%.
ELVN does not currently pay a dividend.
Support: $48.52, $45.87, $43.23. Resistance: $51.59, $56.33, $60.55.
Insider activity: SELLING, 0 buys and 10 sells in the last 90 days.
Nov 6, 2026: Analyst Keeps $78 Target and Buy Rating on Enliven Therapeutics